ZA201204224B - Uracil or thymine derivative for treatting hepatitis c - Google Patents

Uracil or thymine derivative for treatting hepatitis c

Info

Publication number
ZA201204224B
ZA201204224B ZA2012/04224A ZA201204224A ZA201204224B ZA 201204224 B ZA201204224 B ZA 201204224B ZA 2012/04224 A ZA2012/04224 A ZA 2012/04224A ZA 201204224 A ZA201204224 A ZA 201204224A ZA 201204224 B ZA201204224 B ZA 201204224B
Authority
ZA
South Africa
Prior art keywords
treatting
uracil
hepatitis
thymine derivative
thymine
Prior art date
Application number
ZA2012/04224A
Other languages
English (en)
Inventor
Xiaochun Lou
Geoff G Z Zhang
Brian J Kotecki
John E Hangeveld
Yi Gao
Shuang Chen
David A Betebenner
Pamela L Donner
Peggy P Huang
Warren M Kati
Yaya Liu
Clarence J Maring
John K Pratt
Todd W Rockway
Michael D Tufano
Dachun Liu
Kathy Sarris
Rodger F Henry
Anthony R Haight
Ii Thaddeus S Franczyk
David M Barnes
David A Degoey
Charles A Flentge
Douglas K Hutchinson
Allan C Krueger
Kenton L Longenecker
Christopher E Motter
John T Randolph
Kent D Stewart
Rolf Wagner
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39948002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201204224(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of ZA201204224B publication Critical patent/ZA201204224B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Peptides Or Proteins (AREA)
ZA2012/04224A 2007-09-17 2012-06-08 Uracil or thymine derivative for treatting hepatitis c ZA201204224B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97287707P 2007-09-17 2007-09-17
US9679108P 2008-09-13 2008-09-13

Publications (1)

Publication Number Publication Date
ZA201204224B true ZA201204224B (en) 2015-12-23

Family

ID=39948002

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA2012/04224A ZA201204224B (en) 2007-09-17 2012-06-08 Uracil or thymine derivative for treatting hepatitis c
ZA2012/04223A ZA201204223B (en) 2007-09-17 2012-06-08 Uracil or thymine derivative for treating hepatitis c

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA2012/04223A ZA201204223B (en) 2007-09-17 2012-06-08 Uracil or thymine derivative for treating hepatitis c

Country Status (30)

Country Link
US (3) US8415351B2 (cg-RX-API-DMAC7.html)
EP (2) EP2222646B1 (cg-RX-API-DMAC7.html)
JP (2) JP5734654B2 (cg-RX-API-DMAC7.html)
KR (2) KR101660360B1 (cg-RX-API-DMAC7.html)
CN (2) CN101801935B (cg-RX-API-DMAC7.html)
AR (2) AR070027A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008302448B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0816994B8 (cg-RX-API-DMAC7.html)
CA (2) CA2976793A1 (cg-RX-API-DMAC7.html)
CL (2) CL2008002794A1 (cg-RX-API-DMAC7.html)
CO (1) CO6260076A2 (cg-RX-API-DMAC7.html)
CR (2) CR11316A (cg-RX-API-DMAC7.html)
DO (2) DOP2010000084A (cg-RX-API-DMAC7.html)
ES (1) ES2453591T3 (cg-RX-API-DMAC7.html)
GT (1) GT201000061A (cg-RX-API-DMAC7.html)
IL (1) IL204547A (cg-RX-API-DMAC7.html)
IN (1) IN2012DN05113A (cg-RX-API-DMAC7.html)
MX (2) MX2010002905A (cg-RX-API-DMAC7.html)
MY (1) MY162760A (cg-RX-API-DMAC7.html)
NZ (3) NZ600371A (cg-RX-API-DMAC7.html)
PA (1) PA8796201A1 (cg-RX-API-DMAC7.html)
PE (2) PE20090705A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013500365A1 (cg-RX-API-DMAC7.html)
RU (2) RU2543620C2 (cg-RX-API-DMAC7.html)
SG (1) SG183733A1 (cg-RX-API-DMAC7.html)
TW (2) TWI534137B (cg-RX-API-DMAC7.html)
UA (1) UA117800C2 (cg-RX-API-DMAC7.html)
UY (1) UY31344A1 (cg-RX-API-DMAC7.html)
WO (1) WO2009039127A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201204224B (cg-RX-API-DMAC7.html)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2014147354A (ru) 2007-09-17 2015-07-10 Эббви Бахамаз Лтд. Пиримидины, которые могут быть использованы в качестве противоинфекционных средств, и их применения
NZ600371A (en) 2007-09-17 2014-07-25 Abbvie Bahamas Ltd Uracil or thymine derivative for treating hepatitis c
CN101918369B (zh) * 2007-09-17 2016-02-24 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
CN102099351A (zh) * 2007-11-16 2011-06-15 先灵公司 3-杂环取代的吲哚衍生物及其使用方法
WO2010010017A1 (en) 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
CA2736472A1 (en) 2008-09-26 2010-04-01 F. Hoffmann-La Roche Ag Pyrine or pyrazine derivatives for treating hcv
CA2753825C (en) * 2009-03-24 2017-10-17 Abbott Laboratories Process for preparing substituted pyrimidine antiviral compound
MX2011010047A (es) * 2009-03-25 2011-10-11 Abbott Lab Compuestos antivirales y usos de los mismos.
EP2411007A4 (en) * 2009-03-27 2012-12-05 Uab Research Foundation MODULATION OF IRES-MEDIATED TRANSLATION
EP2421831A1 (en) 2009-04-25 2012-02-29 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
TWI428332B (zh) 2009-06-09 2014-03-01 Hoffmann La Roche 雜環抗病毒化合物
CA2762675A1 (en) 2009-06-24 2010-12-29 F. Hoffmann-La Roche Ag Heterocyclic antiviral compound
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
CN102498100A (zh) 2009-09-21 2012-06-13 弗·哈夫曼-拉罗切有限公司 抗病毒杂环化合物
CA2778206A1 (en) * 2009-11-21 2011-05-26 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
CA2780526A1 (en) 2009-12-14 2011-06-23 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
US9216952B2 (en) 2010-03-23 2015-12-22 Abbvie Inc. Process for preparing antiviral compound
MX2012014235A (es) 2010-07-07 2013-01-28 Hoffmann La Roche Compuestos hetericiclicos antiviricos.
CR20180412A (es) 2010-07-16 2018-11-01 Abbvie Ireland Unlimited Co Proceso para preparar compuestos antivirales
AU2015201698B2 (en) * 2010-07-16 2017-02-02 Abbvie Ireland Unlimited Company Process for preparing antiviral compounds
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
EP3461556A1 (en) 2010-07-16 2019-04-03 AbbVie Ireland Unlimited Company Phosphine ligands for catalytic reactions
RU2436786C1 (ru) * 2010-07-23 2011-12-20 Александр Васильевич Иващенко Замещенные индолы, противовирусный активный компонент, способ получения и применения
WO2012020725A1 (ja) * 2010-08-10 2012-02-16 塩野義製薬株式会社 Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体
KR101382730B1 (ko) 2010-08-13 2014-04-08 에프. 호프만-라 로슈 아게 헤테로환형 항바이러스성 화합물
CN102675092B (zh) * 2011-03-14 2014-11-05 江苏中丹药物研究有限公司 一种制备2-芳基-2,2-二甲基乙酸甲酯的方法
US9248193B2 (en) 2011-03-18 2016-02-02 Abbvie Inc. Formulations of phenyl uracil compounds
SG10201602384VA (en) * 2011-03-31 2016-05-30 Konstanze Schäfer Perfluorinated compounds for the non-viral transfer of nucleic acids
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
JP5734124B2 (ja) * 2011-07-21 2015-06-10 株式会社 東邦アーステック １，３−ジヨードヒダントイン類の製造方法
CN104024241B (zh) 2011-08-01 2016-01-20 大日本住友制药株式会社 尿嘧啶衍生物和其用于医学目的的用途
AU2015200715A1 (en) * 2011-10-21 2015-03-05 Abbvie Ireland Unlimited Company Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
GB2506086A (en) 2011-10-21 2014-03-19 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
EA026559B1 (ru) 2012-05-15 2017-04-28 Новартис Аг Соединения и композиции для ингибирования активности abl1, abl2 и bcr-abl1
KR20150008406A (ko) 2012-05-15 2015-01-22 노파르티스 아게 Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체
CN104379574B (zh) 2012-05-15 2017-03-01 诺华股份有限公司 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物
HRP20180695T1 (hr) 2012-05-15 2018-06-01 Novartis Ag Derivati benzamida za inhibiranje aktivnosti od abl1, abl2 i bcr-abl1
CN104379145A (zh) 2012-06-27 2015-02-25 艾伯维公司 Abt-450和利托那韦和例如abt-072和/或abt-333用于在治疗hcv中使用的联合治疗
WO2014031791A1 (en) 2012-08-21 2014-02-27 Abbvie Inc. Process for preparing antiviral compounds
AU2013330993B2 (en) 2012-10-18 2018-03-01 Abbvie Inc. Formulations of pyrimidinedione derivative compounds
JP2014101316A (ja) * 2012-11-20 2014-06-05 Toyobo Co Ltd ベンゾ［１，２−ｄ；４，５−ｄ’］ビスチアゾール化合物の製造方法
CA2916912A1 (en) 2013-07-02 2015-01-08 Abbvie Inc. Methods for treating hcv
JP6423873B2 (ja) 2013-07-08 2018-11-14 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 有害生物防除剤としての６員ｃ−ｎ−結合アリールスルフィド誘導体及びアリールスルホキシド誘導体
EP3043803B1 (en) 2013-09-11 2022-04-27 Emory University Nucleotide and nucleoside compositions and their uses
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
EP3099295A1 (en) 2014-01-28 2016-12-07 Abbvie Inc. Dose adjustment in combination therapy of hepatitis c
DK3102576T3 (da) 2014-02-03 2019-07-22 Vitae Pharmaceuticals Llc Dihydropyrrolopyridininhibitorer af ror-gamma
CN106065009B (zh) * 2014-06-28 2019-03-01 广东东阳光药业有限公司 作为丙型肝炎抑制剂的化合物及其在药物中的应用
WO2016004513A1 (en) * 2014-07-11 2016-01-14 Simon Fraser University Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods
EP3174868B1 (en) 2014-08-01 2021-08-25 Nuevolution A/S Compounds active towards bromodomains
WO2016040588A1 (en) 2014-09-11 2016-03-17 Abbvie Inc. Treatment of hcv by administering four different anti-hcv compounds with food
MX371304B (es) 2014-10-14 2020-01-24 Vitae Pharmaceuticals Llc Dihidropirrolopiridinas inhibidoras del receptor huérfano-gamma.
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
RU2590952C1 (ru) * 2015-05-26 2016-07-10 Вячеслав Энгельсович Семёнов Средство гепатопротекторного действия
WO2016196280A1 (en) 2015-06-02 2016-12-08 E I Du Pont De Nemours And Company Heterocycle-substituted bicyclic pesticides
WO2017019828A1 (en) * 2015-07-30 2017-02-02 Bristol-Myers Squibb Company Aryl substituted bicyclic heteroaryl compounds
WO2017024018A1 (en) 2015-08-05 2017-02-09 Vitae Pharmaceuticals, Inc. Modulators of ror-gamma
AU2016355710B2 (en) 2015-11-20 2021-03-25 Vitae Pharmaceuticals, Llc Modulators of ROR-gamma
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
UA126583C2 (uk) 2017-07-24 2022-11-02 Вітае Фармасьютікалс, Ллс ІНГІБІТОРИ ROR<font face="Symbol">g</font>
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CN107266373A (zh) * 2017-08-01 2017-10-20 安徽拜善晟制药有限公司 一种原料药达沙布韦的制备方法
US11613543B2 (en) 2018-03-26 2023-03-28 Novartis Ag Substituted pyrrolo[2,3-d]pyrimidines as Bruton's Tyrosine Kinase inhibitors
CN110483496B (zh) * 2019-07-17 2021-05-04 杭州市西溪医院 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用
EP4031247A1 (en) * 2019-09-16 2022-07-27 Novartis AG Bifunctional degraders and their methods of use
EP3819006A1 (en) 2019-11-05 2021-05-12 Technische Universität Dresden Compounds with thymine skeleton for use in medicine
CN111518036A (zh) * 2020-04-29 2020-08-11 杭州勇诚睿生物科技有限公司 一种达沙布韦关键中间体的制备方法
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239888A (en) * 1974-11-04 1980-12-16 Pfizer Inc. 1-Phenyluracils
JPS60243017A (ja) 1984-05-16 1985-12-03 Kyowa Hakko Kogyo Co Ltd 抗けいれん組成物
US5084084A (en) 1989-07-14 1992-01-28 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
AU627906B2 (en) 1989-07-14 1992-09-03 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
CA2036304C (en) 1990-02-15 2001-04-17 Takehiko Naka Pyrimidinedione derivatives, their production and use
NL9001075A (cg-RX-API-DMAC7.html) 1990-05-04 1991-12-02 Duphar Int Res
EP0489480A1 (en) * 1990-12-05 1992-06-10 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
JPH05213755A (ja) 1992-02-07 1993-08-24 Nikko Kyodo Co Ltd 肝臓障害治療薬
DE19528305A1 (de) 1995-08-02 1997-02-06 Bayer Ag Substituierte Phenyluracile
CZ303435B6 (cs) 1999-12-06 2012-09-12 F. Hoffmann-La Roche Ag 4-Pyrimidinyl-N-acyl-1-fenylalanin, meziprodukt pro jeho prípravu a farmaceutická kompozice
US6380387B1 (en) 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
RU2264395C2 (ru) * 2000-02-04 2005-11-20 Сумитомо Кемикал Компани, Лимитед Производные урацила, гербицидная композиция, способ борьбы с сорняками и промежуточные продукты (варианты)
IL167955A (en) 2000-02-04 2007-10-31 Sumitomo Chemical Co Inilines are converted by troiril
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
TW200505872A (en) * 2003-06-13 2005-02-16 Lg Life Science Ltd Hepatitis C virus inhibitors
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
AR061570A1 (es) * 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto
RU2014147354A (ru) * 2007-09-17 2015-07-10 Эббви Бахамаз Лтд. Пиримидины, которые могут быть использованы в качестве противоинфекционных средств, и их применения
CN101918369B (zh) * 2007-09-17 2016-02-24 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
NZ600371A (en) 2007-09-17 2014-07-25 Abbvie Bahamas Ltd Uracil or thymine derivative for treating hepatitis c
WO2010010017A1 (en) 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds

Also Published As

Publication number Publication date
RU2543620C2 (ru) 2015-03-10
NZ618277A (en) 2015-07-31
RU2010114828A (ru) 2011-10-27
JP2010539186A (ja) 2010-12-16
AU2008302448B2 (en) 2014-11-06
KR20150117632A (ko) 2015-10-20
TWI534137B (zh) 2016-05-21
US20140235638A1 (en) 2014-08-21
KR101660360B1 (ko) 2016-09-27
KR20100068289A (ko) 2010-06-22
US9095590B2 (en) 2015-08-04
WO2009039127A1 (en) 2009-03-26
CA2699981C (en) 2017-08-22
US20110070193A1 (en) 2011-03-24
DOP2010000084A (es) 2010-06-15
CL2013000372A1 (es) 2013-10-04
TW201443027A (zh) 2014-11-16
AR087472A2 (es) 2014-03-26
ES2453591T3 (es) 2014-04-08
BRPI0816994A2 (pt) 2015-03-24
CR20150238A (es) 2015-07-01
CA2699981A1 (en) 2009-03-26
CN101801935A (zh) 2010-08-11
IL204547A (en) 2016-04-21
NZ584720A (en) 2012-07-27
CA2976793A1 (en) 2009-03-26
CN102746239B (zh) 2016-02-10
IN2012DN05113A (cg-RX-API-DMAC7.html) 2015-10-23
US8685991B2 (en) 2014-04-01
BRPI0816994B1 (pt) 2019-12-24
CN101801935B (zh) 2014-12-03
AU2008302448A1 (en) 2009-03-26
UY31344A1 (es) 2009-04-30
DOP2010000396A (es) 2013-12-31
CR11316A (es) 2010-10-05
EP2725015A1 (en) 2014-04-30
CL2008002794A1 (es) 2009-09-04
BRPI0816994B8 (pt) 2021-05-25
IL204547A0 (en) 2010-11-30
CO6260076A2 (es) 2011-03-22
PH12013500365A1 (en) 2014-09-08
PA8796201A1 (es) 2009-04-23
US20120213733A1 (en) 2012-08-23
KR101552474B1 (ko) 2015-09-11
US8415351B2 (en) 2013-04-09
RU2013104270A (ru) 2014-08-10
MX338555B (es) 2016-04-20
EP2222646B1 (en) 2014-01-22
PE20090705A1 (es) 2009-07-17
CN102746239A (zh) 2012-10-24
EP2222646A1 (en) 2010-09-01
TWI437994B (zh) 2014-05-21
AR070027A1 (es) 2010-03-10
MY162760A (en) 2017-07-14
RU2599635C2 (ru) 2016-10-10
MX2010002905A (es) 2010-07-05
GT201000061A (es) 2012-03-26
JP5734654B2 (ja) 2015-06-17
JP2013049681A (ja) 2013-03-14
HK1147256A1 (en) 2011-08-05
PE20130209A1 (es) 2013-03-24
SG183733A1 (en) 2012-09-27
TW200918066A (en) 2009-05-01
NZ600371A (en) 2014-07-25
ZA201204223B (en) 2015-12-23
UA117800C2 (uk) 2018-10-10

Similar Documents

Publication Publication Date Title
ZA201204224B (en) Uracil or thymine derivative for treatting hepatitis c
ZA201003875B (en) Novel pyrimidine derivatives
LT2754660T (lt) Piridazinono dariniai
PL2154967T3 (pl) Pochodne pirymidyny
IL192610A0 (en) Pyrimidine derivatives
IL200831A0 (en) Novel adenine compounds
IL202376A0 (en) Pyridazinone derivatives
AP2874A (en) Antiviral compounds
IL200661A0 (en) Heterocyclic antiviral compounds
IL235555A0 (en) A purine is converted to a pyrimidine
IL196876A0 (en) 2-(heterocyclylbenzyl)pyridazinone derivatives
IL202623A0 (en) Antiviral compounds
ZA201003438B (en) Antiviral nucleoside compounds
EP2234623A4 (en) ANTIVIRAL CONNECTIONS
PL2367815T3 (pl) Pochodne pirydazynonowe
ZA201003815B (en) Heterocyclic antiviral compounds
IL212636A0 (en) Pyridazinone derivatives
GB0614579D0 (en) Pyrimidine derivatives
PL2280962T3 (pl) Pochodne pirydazynonowe
ZA201000107B (en) Pyrimidine derivatives 934
IL195018A0 (en) Piperidinyl pyrimidine derivatives
EP2094704A4 (en) CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES
ZA200806845B (en) Heterocyclic antiviral compounds
ZA201000662B (en) Antiviral compounds